omniture

中國疼痛戰(zhàn)略發(fā)布

全方位優(yōu)化疼痛管理,讓患者樂享無痛人生
輝瑞普強(qiáng)
2020-11-07 07:49 6399
在今天舉辦的第三屆中國國際進(jìn)口博覽會(huì)上,“有V-無痛”中國疼痛戰(zhàn)略發(fā)布會(huì)在輝瑞普強(qiáng),即未來的暉致(Viatris)展臺(tái)隆重召開。

上海2020年11月6日 /美通社/ -- 在今天舉辦的第三屆中國國際進(jìn)口博覽會(huì)上,“有V?無痛”中國疼痛戰(zhàn)略發(fā)布會(huì)在輝瑞普強(qiáng),即未來的暉致(Viatris)展臺(tái)隆重召開。來自國家衛(wèi)生健康委相關(guān)部門領(lǐng)導(dǎo)、疼痛領(lǐng)域的權(quán)威專家學(xué)者等共同啟動(dòng)了中國疼痛戰(zhàn)略,以打造我國特色疼痛診療之路,為疼痛學(xué)科及多學(xué)科協(xié)作系統(tǒng)性規(guī)劃,開啟疼痛醫(yī)學(xué)新篇章,助力實(shí)現(xiàn)無痛中國夢(mèng)。啟動(dòng)會(huì)上,首部中國疼痛防控與健康促進(jìn)戰(zhàn)略藍(lán)皮書 -- 《中國疼痛醫(yī)學(xué)發(fā)展報(bào)告(2020)》成功發(fā)布,并啟動(dòng)“疼痛防治基層行”項(xiàng)目,幫助基層規(guī)范診療。

中國疼痛戰(zhàn)略發(fā)布會(huì)
中國疼痛戰(zhàn)略發(fā)布會(huì)

國家衛(wèi)生健康委中國人口宣傳教育中心副主任石琦表示:“2020年是我國全面建成小康社會(huì)收官之年。全民健康作為全面小康的重要條件,沒有全民健康,就沒有全面小康。慢性疼痛作為威脅人類健康的一種疾病,在我國患病人群龐大,已成為社會(huì)重大負(fù)擔(dān),因此推動(dòng)疼痛事業(yè)是民之所需、醫(yī)之所為、政之所向。此次中國疼痛戰(zhàn)略的推出,從戰(zhàn)略規(guī)劃、藍(lán)皮書、防治基層行等方面發(fā)動(dòng)各界力量,不斷促進(jìn)疼痛診療水平的提升,擴(kuò)大疼痛醫(yī)療服務(wù)的可及性,推動(dòng)我國疼痛診療服務(wù)的規(guī)范化、標(biāo)準(zhǔn)化、同質(zhì)化,以更好地滿足疼痛患者需求,為提升全民健康素養(yǎng)、促進(jìn)健康中國建設(shè)而不懈努力?!?/p>

多維度發(fā)力 推動(dòng)中國疼痛戰(zhàn)略加速實(shí)施

疼痛是人體受到損害或疾病侵襲的預(yù)警性信號(hào),是一種常見的臨床癥狀,而慢性疼痛是一種獨(dú)立的疾病。目前,疼痛已成為繼心腦血管疾病、腫瘤之后的第三大健康問題。疼痛不僅使患者痛苦,還常常造成心理應(yīng)激和情緒障礙,增加并發(fā)癥的發(fā)生,嚴(yán)重甚至不能獨(dú)立生活,出現(xiàn)自殺行為。據(jù)統(tǒng)計(jì),我國慢性疼痛患者超過3億人,且每年以1000-2000萬的速度快速增長[1],呈現(xiàn)出快速增?和低齡化趨勢(shì),給患者及家庭帶來沉重的經(jīng)濟(jì)負(fù)擔(dān)和身心負(fù)擔(dān)。

數(shù)據(jù)顯示,對(duì)于慢性疼痛,我國患者的知曉率僅為14.3%,就診率不足60%,經(jīng)過治療后,完全緩解率不足20%[2],[3]。在我國,大眾的鎮(zhèn)痛觀念相對(duì)落后,對(duì)疼痛認(rèn)知存在諸多誤區(qū),70%百姓對(duì)待疼痛選擇忍耐[4];加之慢性疼痛患者較為分散,各??茖?duì)疼痛關(guān)注度不足,未形成相應(yīng)的協(xié)作機(jī)制,且醫(yī)生的疼痛 診療水平有待提高,用藥不規(guī)范普遍存在。特別是對(duì)于基層的疼痛患者,受醫(yī)療服務(wù)條件限制,無法及時(shí)診療導(dǎo)致病情加重,使得中國慢性疼痛診治現(xiàn)狀極不樂觀。

“當(dāng)前我國疼痛領(lǐng)域?qū)W科的發(fā)展仍面臨諸多短板與挑戰(zhàn),存在治療現(xiàn)狀不樂觀、供給需求不平衡、技術(shù)規(guī)范不足、人才配備不均衡等問題,這些都對(duì)疼痛領(lǐng)域的發(fā)展提出了更緊迫要求?!敝袊t(yī)師協(xié)會(huì)疼痛科醫(yī)師分會(huì)會(huì)長、中日醫(yī)院疼痛科主任樊碧發(fā)表示:“此次中國疼痛戰(zhàn)略規(guī)劃的發(fā)布,從國家、學(xué)科臨床、醫(yī)生、患者、大眾五大維度發(fā)力,第一階段重點(diǎn)建設(shè)穩(wěn)固基礎(chǔ),融合發(fā)展創(chuàng)新利遠(yuǎn),將學(xué)科建設(shè)與學(xué)科協(xié)作互融互動(dòng),兩者協(xié)同發(fā)展推動(dòng)政策融動(dòng);同時(shí)制定臨床規(guī)范,優(yōu)化診療工具,讓疼痛治療更加可行可及,并且要向大眾講好‘疼痛故事’,加強(qiáng)公眾教育、提高公眾疼痛防治意識(shí),多個(gè)層面積極采取措施,阻止和減少慢性疼痛給人類社會(huì)帶來的影響。”

疼痛藍(lán)皮書賦能疼痛防控,助疼痛領(lǐng)域新發(fā)展

隨著社會(huì)經(jīng)濟(jì)發(fā)展,人民生活方式的改變,以及社會(huì)老齡化進(jìn)一步加劇,醫(yī)療服務(wù)需求增加,醫(yī)療成本大幅增長,導(dǎo)致疼痛醫(yī)療衛(wèi)生發(fā)展迫在眉睫。2017年國務(wù)院印發(fā)了《中國防治慢性病中長期規(guī)劃(2017 - 2025)》,將慢痛管理與慢病管理并行同行,使慢痛管理成為慢病中長期規(guī)劃的重要組成部分。

為推動(dòng)健康中國戰(zhàn)略實(shí)施,提高疼痛患者的生活質(zhì)量,會(huì)上發(fā)布了首部中國疼痛防控與健康促進(jìn)戰(zhàn)略藍(lán)皮書 -- 《中國疼痛醫(yī)學(xué)發(fā)展報(bào)告(2020)》。藍(lán)皮書集結(jié)了國內(nèi)政策、臨床、公衛(wèi)權(quán)威專家共同制定,由清華大學(xué)出版社出版,面向政策決策者、臨床醫(yī)護(hù)工作者、患者與大眾,融合疼痛學(xué)科國家政策與臨床現(xiàn)狀的洞察解析,對(duì)疼痛領(lǐng)域作出了全方位的總結(jié)與解讀。

疾控領(lǐng)域?qū)I(yè)人士介紹,疼痛藍(lán)皮書總結(jié)了疼痛學(xué)科領(lǐng)域基礎(chǔ)研究與臨床實(shí)踐的精華,從疼痛認(rèn)知、疾病負(fù)擔(dān)、診斷與臨床評(píng)估、疼痛治療等多方面做出了全面的闡釋,尤其強(qiáng)調(diào)了機(jī)制鎮(zhèn)痛和基于生物-心理-社會(huì)醫(yī)學(xué)模式的疼痛綜合管理,有助于推動(dòng)疼痛科普宣傳工作,促進(jìn)全民對(duì)疼痛的正確認(rèn)知。同時(shí),藍(lán)皮書為疼痛政策制定與戰(zhàn)略實(shí)施提供理論保障,為我國疼痛領(lǐng)域發(fā)展提供政策建議,填補(bǔ)醫(yī)學(xué)科學(xué)發(fā)展史上有關(guān)疼痛政策研究的空白。

輝瑞普強(qiáng)大中華區(qū)首席醫(yī)學(xué)官,未來的暉致大中華區(qū)首席醫(yī)學(xué)官及臨床研究負(fù)責(zé)人于巍表示:“我們一直致力于健康知識(shí)的傳播,在疼痛慢病管理領(lǐng)域宣傳正確健康的理念,也一直在支持疼痛戰(zhàn)略的實(shí)施、規(guī)范診療教育,以及未來質(zhì)控中心的建設(shè)。我們將不遺余力,在中國疼痛領(lǐng)域發(fā)展的道路上鼎力支持,為無痛中國夢(mèng)的實(shí)現(xiàn)不斷注能?!?/p>

推動(dòng)戰(zhàn)略加速實(shí)施,力促基層疼痛規(guī)范診療

為了規(guī)范基層疼痛診療,提高大眾疼痛防治能力,“疼痛防治基層行”項(xiàng)目的啟動(dòng)將優(yōu)質(zhì)醫(yī)療下沉到基層,擴(kuò)大醫(yī)療衛(wèi)生服務(wù)覆蓋面,以惠及更多疼痛患者。該項(xiàng)目以線上+線下結(jié)合模式進(jìn)行,通過舉辦線下多學(xué)科交流會(huì)、疼痛相關(guān)疾病診療線上培訓(xùn)會(huì)及疼痛相關(guān)技術(shù)規(guī)范巡講會(huì)、示范中心短期培訓(xùn)班、公眾健康科普宣教、患者教育等一系列活動(dòng)。預(yù)計(jì)覆蓋約200個(gè)縣、500家醫(yī)院,參與醫(yī)生4200人次,受益公眾及患者13000人次。

樊碧發(fā)教授表示:“隨著人民群眾醫(yī)療服務(wù)需求持續(xù)釋放,以及新醫(yī)改、分級(jí)診療制度的不斷推動(dòng),疼痛學(xué)科發(fā)展重心下沉漸成趨勢(shì)。此次疼痛防治基層行的開展將有助于切實(shí)提高基層醫(yī)生和縣級(jí)醫(yī)院對(duì)骨關(guān)節(jié)及疼痛相關(guān)疾病的識(shí)別及診治水平,提高公眾和患者對(duì)于骨關(guān)節(jié)疾病的認(rèn)知水平與防治保健技能,對(duì)于貫徹落實(shí)健康中國戰(zhàn)略、推進(jìn)基層衛(wèi)生醫(yī)療服務(wù)能力提升具有重要意義?!?/p>

輝瑞普強(qiáng)中國區(qū)醫(yī)院業(yè)務(wù)副總裁,未來的暉致中國醫(yī)院業(yè)務(wù)負(fù)責(zé)人任強(qiáng)表示:“暉致將是一家著眼于醫(yī)療健康未來的公司。我們的使命是幫助世界各地的人們?cè)谏拿總€(gè)階段生活得更加健康。我們致力于成為中國醫(yī)療衛(wèi)生體系的重要合作伙伴,并將充分發(fā)揮自身的全球資源和醫(yī)學(xué)專業(yè)優(yōu)勢(shì),為中國疼痛患者提供有效的解決方案,并積極履行企業(yè)社會(huì)責(zé)任,與疼痛領(lǐng)域?qū)<夜餐苿?dòng)疼痛知識(shí)的科普宣教,讓更多的人認(rèn)識(shí)和關(guān)注疼痛。未來,我們希望能與社會(huì)各界展開更為廣泛的合作,幫助中國疼痛患者樂享無痛人生!”

Forward-Looking Statements

This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan, which will immediately follow the proposed separation of the Upjohn business (the “Upjohn Business”) from Pfizer Inc. (“Pfizer”) (the “proposed transaction”), the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding Pfizer’s, Mylan’s, the Upjohn Business’s or the combined company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward looking statements may often be identified by the use of words such as “will”, “may”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: ongoing challenges and uncertainties posed by the COVID-19 pandemic for businesses and governments around the world; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws; the parties’ ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis; the integration of Mylan and the Upjohn Business being more difficult, time consuming or costly than expected; Mylan’s, the Upjohn Business’s and the combined company’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all or to successfully integrate Mylan and the Upjohn Business; customer loss and business disruption being greater than expected following the proposed transaction; the retention of key employees being more difficult following the proposed transaction; Mylan’s, the Upjohn Business’s or the combined company’s liquidity, capital resources and ability to obtain financing; any regulatory, legal or other impediments to Mylan’s, the Upjohn Business’s or the combined company’s ability to bring new products to market, including but not limited to where Mylan, the Upjohn Business or the combined company uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); success of clinical trials and Mylan’s, the Upjohn Business’s or the combined company’s ability to execute on new product opportunities; any changes in or difficulties with Mylan’s, the Upjohn Business’s or the combined company’s manufacturing facilities, including with respect to remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on Mylan’s, the Upjohn Business’s or the combined company’s consolidated financial condition, results of operations and/or cash flows; Mylan’s, the Upjohn Business’s and the combined company’s ability to protect their respective intellectual property and preserve their respective intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; actions and decisions of healthcare and pharmaceutical regulators; the impacts of competition; changes in the economic and financial conditions of the Upjohn Business or the business of Mylan or the combined company; the impact of outbreaks, epidemics or pandemics, such as the COVID-19 pandemic; uncertainties regarding future demand, pricing and reimbursement for Mylan’s, the Upjohn Business’s or the combined company’s products; and uncertainties and matters beyond the control of management and other factors described under “Risk Factors” in each of Pfizer’s, Newco’s and Mylan’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission (“SEC”). These risks, as well as other risks associated with Mylan, the Upjohn Business, the combined company and the proposed transaction are also more fully discussed in the Registration Statement on Form S-4, as amended, which includes a proxy statement/prospectus (as amended, the “Form S-4”), which was filed by Newco with the SEC on October 25, 2019 and declared effective by the SEC on February 13, 2020, the Registration Statement on Form 10, which includes an information statement (the “Form 10”), which was filed by Newco with the SEC on June 12, 2020 and declared effective by the SEC on June 30, 2020, a definitive proxy statement, which was filed by Mylan with the SEC on February 13, 2020 (the “Proxy Statement”), and a prospectus, which was filed by Newco with the SEC on February 13, 2020 (the “Prospectus”). You can access Pfizer’s, Mylan’s and Newco’s filings with the SEC through the SEC website at www.sec.gov or through Pfizer’s or Mylan’s website, as applicable, and Pfizer and Mylan strongly encourage you to do so. Except as required by applicable law, Pfizer, Mylan and Newco undertake no obligation to update any statements herein for revisions or changes after this communication is made.

[1] Xiao H, et al. Med Sci Monit. 2018;24:7809-7819.

[2] 2020年中国疼痛防控与健康促进战略蓝皮书政策研究报告.

[3] 毛冬梅, 姚旌, 何霞,等. 贵阳市社区医院慢性疼痛诊疗现状及患者满意度调查[J]. 贵阳医学院学报, 2019, 044(011):1301-1304,1315.

[4]中国疼痛认知调研

 

 

消息來源:輝瑞普強(qiáng)
China-PRNewsire-300-300.png
醫(yī)藥健聞
微信公眾號(hào)“醫(yī)藥健聞”發(fā)布全球制藥、醫(yī)療、大健康企業(yè)最新的經(jīng)營動(dòng)態(tài)。掃描二維碼,立即訂閱!
collection
分享至X
分享至X